Latest Publishing News

News Corporation reported a 9% revenue increase to $2.185 billion in Q3 FY2026, driven by growth across its media and real estate segments, but net income attributable to stockholders declined 14% amid rising costs and restructuring.

Aspermont Limited reported a 15% revenue increase in Q2 FY26, driven by a surge in non-subscriptions revenue and steady subscriptions. The company is progressing its AI-enabled data platform build, funded internally, with cash flow positivity expected soon.

News Corporation posted a solid third quarter with revenues climbing 9% to $2.19 billion and net income from continuing operations up 13% to $121 million, driven by robust performances in Digital Real Estate Services, Dow Jones, and Book Publishing.

Aland Equity Group (ASX: AEG) reveals advanced talks on a property funds management transaction linked to its chairman, explaining recent unusual share price activity.

Pacgold has confirmed new shallow gold mineralisation at its Vertigo deposit within the White Dam Project, suggesting a potential increase to its Mineral Resource Estimate. Infill drilling results support upgrading resource confidence, with further drilling planned to refine the resource and support mine planning.

Connected Minerals Limited (ASX:CML) confirms it disclosed its binding acquisition of Frontier Group CRM and associated $4.5 million capital raising promptly after finalising agreements, addressing ASX concerns over earlier market activity.

PTR Minerals has received the final batch of assay results from its Rosewood East drilling, revealing consistent, shallow, and high-grade heavy mineralisation. The company remains on track to deliver its maiden Mineral Resource Estimate in Q2 2026.

Nine Entertainment’s acquisition of QMS Media and sale of Nine Radio mark a strategic pivot, with strong Q3 digital and subscription revenue growth cushioning a cautious Q4 advertising environment.

LTR Pharma highlights SPONTAN's 5x faster absorption and validated safety, backed by over 1,000 Australian prescriptions and strategic partnerships as it targets FDA approval and US market entry.

Noxopharm’s SOF-16 active ingredient demonstrated potent anti-inflammatory activity in patient-derived samples of systemic lupus erythematosus and rheumatoid arthritis, advancing its Sofra™ platform beyond topical applications.

Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.

OpenLearning accelerated its SaaS annual recurring revenue by 35% year-on-year to $3.192 million in Q1 FY26, propelled by larger multi-year LMS contracts and ongoing AI platform enhancements.